NanoString Highlights Record Number of nCounter-Based Abstracts at the 2018 Annual Meeting of the American Society of Clinical Oncology

More than 50 abstracts highlight the diverse capabilities of NanoString’s technologies in immuno-oncology, biomarker development and validation, and cancer characterization

SEATTLE, May 31, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today highlighted a record number of abstracts that will be presented at the American Society of Clinical Oncology (ASCO) conference being held June 1-5, 2018, in Chicago, Illinois.

“We’re proud of the extensive body of nCounter™-enabled research that is being presented at this year’s meeting of the American Society of Clinical Oncology,” said Brad Gray, NanoString’s president and CEO. “This includes important clinical applications of our products for current and potential diagnostic tests for immuno-oncology, breast cancer and lymphoma.”

At least 53 abstracts using NanoString’s technologies will be presented at ASCO, including applications of gene expression profiling in cancer and immuno-therapy using NanoString products like the PanCancer Panel family and IO 360™, as well as diagnostic applications such as subtyping breast cancer and lymphoma.

Below is a subset of abstracts that best illustrate the unique capabilities of NanoString’s technology platforms to span the continuum from biomarker targeted discovery to clinical applications.  A complete list of NanoString-enabled abstracts can be found in the table that follows.

Immuno-oncology
Title: Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data
Date/Time: Monday, June 4, 2018, 3:00pm-4:30pm CT
Author: Marleen Kok, MD
Poster #/Location: 1012/Clinical Science Symposium, Hall D2
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/160551/abstract

Title: Immune gene profiling of pretreatment tumor samples in “real-world” advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4
Date/Time: Monday, June 4, 2018, 1:15pm-4:45pm CT
Author: Elisa A. Rozeman, MD
Poster #/Location: 9585/Board 412
Hyperlink:  Opens in new windowhttps://meetinglibrary.asco.org/record/163660/abstract

Title: Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1
Date/Time: Sunday, June 3, 2018, 8am-11:30am CT
Author: Edward B. Garon, MD
Poster #/Location: 9018/Board 341
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/160279/abstract

Title: Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC)
Date/Time: Monday, April 16 2018, 1pm-5:00pm CT
Author: Nizar M. Tannir, MD
Poster #/Location: 4509/Board 335
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/161707/abstract

Title: Immune profiling of BRCA-mutated breast cancers
Date/Time: Saturday, June 2, 2018, 8:00am-11:30am CT
Author: Jeremy Meyer Force, DO
Poster #/Location: 585/Board 77
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/163391/abstract

Title: Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
Date/Time: Saturday, June 2, 2018, 1:15pm-4:45pm CT
Author: Inge Tinhofer, PhD
Poster #/Location: 6047/Board 35
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/162474/abstract

Title: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody
Date/Time: Monday, June 4, 2018, 1:15pm-4:45pm CT
Author: Sanjiv S. Agarwala, MD
Poster #/Location: 9530/Board 357
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/163453/abstract

Title: Efficacy and genetic analysis for a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic immunotherapy, and ipilimumab combination treatment in patients with stage IIIb-IV unresectable or metastatic melanoma
Date/Time: Monday, June 4, 2018, 1:15pm-4:45pm CT
Author: Robert Hans Ingemar Andtbacka, MD
Poster #/Location: 9541/Board 368
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/163701/abstract

Title: Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide
Date/Time: Saturday, June 2, 2018, 8:00am-11:30am CT
Author: Xiaotong Li, PhD
Poster #/Location: 578/Board 70
Hyperlink:Opens in new window https://meetinglibrary.asco.org/record/162778/abstract

Title: Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials
Date/Time: Monday, April 16 2018, 1pm-5:00pm CT
Author: Saranya Chumsri, MD
Poster #/Location: 577/Board 69
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/162783/abstract

Lymphoma Sub-typing (Lymphmark™)
Title: Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST)
Date/Time: Monday, June 4, 2018, 8am-11:30am CT
Author: Grzegorz S. Nowakowski, MD
Poster #/Location: 7548/Board 185
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/162322/abstract

Title: Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Date/Time: Monday, June 4, 2018, 1pm-5:00pm CT
Author: Martin JS Dyer, PhD
Poster #/Location: 7547/Board 184
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/162360/abstract

Title: Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell Iymphoma (CD5+ DLBCL): Primary analysis of PEARL5 study
Date/Time: Monday, June 4, 2018, 8am-11:30am CT
Author: Kana Miyazaki, MD, PhD
Poster #/Location: 7561/Board 198
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/162387/abstract

Breast Cancer (Prosigna®-PAM50)
Title: SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer
Date/Time: Saturday, June 2, 2018, 8am-11:30am CT
Author: Patricia Villagrasa, PhD
Poster #/Location: TPS1101/Board 181b
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/165311/abstract

Title: PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.
Date/Time: Saturday, June 2, 2018, 1pm-5:00pm CT
Author: Tomás Pascual, MD
Poster #/Location: 1025/Board 106
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/161762/abstract

Title: HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.
Date/Time: Saturday, June 2, 2018, 8am-11:30am CT
Author: Aleix Prat, MD, PhD
Poster #/Location: 509/Board 1
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/161696/abstract

Title: Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial
Date/Time: Saturday, June 2, 2018, 8am-11:30am CT
Author: Sandra M. Swain, MD
Poster #/Location: 580/Board 72
Hyperlink: Opens in new windowhttps://meetinglibrary.asco.org/record/162624/abstract

About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company’s nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,950 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit Opens in new windowwww.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, IO360, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions. All third party trademarks are the property of their respective owners.

Contact:

Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768

Source: NanoString Technologies, Inc.